摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

magnesium citrate | 144-23-0

中文名称
——
中文别名
——
英文名称
magnesium citrate
英文别名
magnesium citrate dibasic;Magnesium;2-(carboxymethyl)-2-hydroxybutanedioate;magnesium;2-(carboxymethyl)-2-hydroxybutanedioate
magnesium citrate化学式
CAS
144-23-0
化学式
C6H6O7*Mg
mdl
——
分子量
214.414
InChiKey
DIXGJWCZQHXZNR-UHFFFAOYSA-L
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    -4.3
  • 重原子数:
    14
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    138
  • 氢给体数:
    2
  • 氢受体数:
    7

安全信息

  • 危险品标志:
    Xi
  • 安全说明:
    S23,S24/25,S26,S36
  • 危险类别码:
    R36/37/38
  • WGK Germany:
    2
  • RTECS号:
    SA4250000
  • 海关编码:
    2918150000

SDS

SDS:3a5706018567b2b8769aeebe00f48c1c
查看

制备方法与用途

柠檬酸镁是一种镁盐,主要用于治疗代谢紊乱和肠道疾病。此外,它还可作为诊断试剂,用于测定血浆和血清中的钙水平。

在制药工业中,柠檬酸镁也有广泛的应用。

反应信息

  • 作为反应物:
    描述:
    magnesium citrate 以 neat (no solvent) 为溶剂, 生成 magnesium oxide
    参考文献:
    名称:
    Hedvall, J. A., Zeitschrift fur anorganische Chemie, 1922, vol. 120, p. 334 - 334
    摘要:
    DOI:
  • 作为产物:
    描述:
    柠檬酸magnesium oxide 作用下, 以 为溶剂, 反应 0.67h, 生成 magnesium citrate
    参考文献:
    名称:
    一种柠檬酸的镁盐及其制备方法和含有该柠檬酸的镁盐的制剂
    摘要:
    本发明涉及精细化工领域,公开了一种柠檬酸的镁盐及其制备方法和含有该柠檬酸的镁盐的制剂。其中,制备方法包括:以摩尔比计,将氧化镁、柠檬酸和水按1:2-2.1:3-4的比例混合,然后在70-90℃下进行加热处理。本发明的方法,不需要进行过滤及浓缩结晶等操作,且制备得到的柠檬酸的镁盐在水中具有明显较大的溶解度,明显拓宽了其应用范围。
    公开号:
    CN106854155A
点击查看最新优质反应信息

文献信息

  • ALDEHYDE INHIBITOR COMPOSITION AND POLYACETAL RESIN COMPOSITION
    申请人:Polyplastics Co., Ltd.
    公开号:EP1683838A1
    公开(公告)日:2006-07-26
    An aldehyde-inhibiting composition inhibiting an aldehyde from an aldehyde-generating source comprises a carboxylic acid hydrazide and a metal salt of a hydroxy polycarboxylic acid (e.g., a salt of citric acid, malic acid, or tartaric acid with an alkaline earth metal) in a proportion of 0.01 to 100 parts by weight relative to 1 part by weight of the carboxylic acidhydrazide. Moreover, a polyacetal resin composition may comprise a polyacetal resin and the aldehyde-inhibiting composition in a proportion of 0.001 to 20 parts by weight of the aldehyde-inhibiting composition relative to 100 parts by weight of the polyacetal resin. To the resin composition, may be added an antioxidant, a heat stabilizer, a processing stabilizer, a weather (light)-resistant stabilizer, an impact resistance improver, a gloss control agent, a sliding improver, a coloring agent, a filler, and others. A small amount of the aldehyde-inhibiting composition efficiently inhibits the aldehyde generation from the polyacetal resin without discoloring the resin.
    一种抑制醛生成源的醛的抑醛组合物包括羧酸酰肼和羟基多羧酸的金属盐(如柠檬酸、苹果酸或酒石酸与碱土金属的盐),相对于 1 份羧酸酰肼的重量比例为 0.01 至 100 份。此外,聚缩醛树脂组合物可包括聚缩醛树脂和醛抑制组合物,其中醛抑制组合物的比例为 0.001 至 20(按聚缩醛树脂的重量计),相对于 100(按聚缩醛树脂的重量计)。在树脂组合物中可添加抗氧化剂、热稳定剂、加工稳定剂、耐候(光)稳定剂、抗冲击性改进剂、光泽控制剂、滑动改进剂、着色剂、填料等。少量的醛抑制组合物就能有效抑制聚缩醛树脂中醛的生成,而不会使树脂变色。
  • Macrolide compositions having improved taste and stability
    申请人:PARI Pharma GmbH
    公开号:EP2098219A1
    公开(公告)日:2009-09-09
    The invention provides an aqueous pharmaceutical composition for administration as an aerosol to the respiratory tract, nose or oropharyngeal region comprising (i) a macrolide having a poor taste and poor chemical stability in aqueous solution; (ii) at least one salt selected from the group consisting of sodium gluconate, sodium aspartate, sodium acetate, sodium lactate, sodium succinate, sodium maleate, magnesium gluconate, magnesium aspartate, magnesium citrate, magnesium acetate, magnesium lactate, magnesium succinate, and magnesium maleate; and (iii) a taste-masking agent different from said salt; wherein (a) the concentration of said macrolide in the composition is in the range of about 0.25 wt.-% to about 15 wt.-%; (b) the molar ratio of said macrolide : said salt is in the range from about 1 : 0.5 to about 1 : 100; (c) the pH of the composition is in the range of about 3 to 9; and (d) the osmolality of the composition is in the range of about 150 mOsmol/kg to about 1500 mOsmol/kg. The invention further provides a method of generating an aerosol, preferably by means of a nebuliser, which uses such an aqueous pharmaceutical composition. The macrolide may be used alone or in combination with other drugs. The composition is suitable to treat inflammatory disorders and/or infections of the respiratory tract. It has an improved taste and stability.
    本发明提供了一种水基药物组合物,可作为气雾剂用于呼吸道、鼻腔或口咽部,该组合物包含 (i) 在水溶液中味道差、化学稳定性差的大环内酯类药物;(ii) 至少一种盐,选自由葡萄糖酸钠、天门冬氨酸钠、醋酸钠、乳酸钠、琥珀酸钠、马来酸钠、葡萄糖酸镁、天门冬氨酸镁、柠檬酸镁、醋酸镁、乳酸镁、琥珀酸镁和马来酸镁组成的组;和 (iii) 不同于所述盐的掩味剂; 其中 (a) 组合物中所述大环内酯的浓度范围为约 0.25 wt.%至约 15 wt.-%; (b) 所述大环内酯与所述盐的摩尔比在约 1 : 0.5 至约 1 : 100 的范围内; (c) 组合物的 pH 值在约 3 至 9 的范围内;以及 (d) 组合物的渗透压在约 150 mOsmol/kg 至约 1500 mOsmol/kg 的范围内。本发明进一步提供了一种产生气雾剂的方法,最好通过雾化器,使用这种水性药物组合物。大环内酯类药物可单独使用,也可与其他药物联合使用。该组合物适用于治疗呼吸道炎症和/或感染。它具有更好的口感和稳定性。
  • Milk Acidification Composition For Powdered Beverage
    申请人:Kraft Foods Global Brands LLC
    公开号:EP2145544A1
    公开(公告)日:2010-01-20
    The present invention relates to instant acidified milk beverages and methods for producing such instant acidified milk beverages. More specifically, the present Invention provides a powdered composition which can be added to a liquid milk product with minimal mixing to produce an instant acidified milk beverage having a smooth texture. Even more specifically, the powdered composition includes at least one edible monobasic salt of polyprotonic acid. The powdered composition may include a buffer salt, and other optional ingredients such as sweetener, thickener, fiber, bulking agent, anti-caking agent, fruit juice solid, flavor, and colorant, etc.
    本发明涉及速溶酸化乳饮料和生产这种速溶酸化乳饮料的方法。更具体地说,本发明提供了一种粉末状组合物,它可以添加到液态奶产品中,只需极少的搅拌,就能生产出质地柔滑的速溶酸化奶饮料。更具体地说,粉末状组合物包括至少一种可食用的多质子酸单碱式盐。粉状组合物可包括缓冲盐和其他可选成分,如甜味剂、增稠剂、纤维、膨松剂、抗结块剂、果汁固体、香精和着色剂等。
  • SAPONIFIED ETHYLENE-VINYL ESTER COPOLYMER COMPOSITION, AND MULTILAYER STRUCTURE USING SAID COMPOSITION
    申请人:The Nippon Synthetic Chemical Industry Co., Ltd.
    公开号:EP3056538A1
    公开(公告)日:2016-08-17
    Provided are: an EVOH resin composition which can exhibit excellent gas-barrier performance after being subjected to a hot water treatment and rarely generates blisters even when being placed under a high-temperature and high-humidity condition; and a multilayered structure including a layer of the resin composition as a gas-barrier layer. A hydrate-formable alkaline earth metal salt having a specific water absorption property, particularly completely or partially dehydrated alkaline earth metal salt of acid, or a mixture thereof. The acid is selected from the group consisting of lactic acid, silicic acid, phosphoric acid, and citric acid. The partially dehydrated alkaline earth metal salt of the salt has a water content of 50 wt% or less.
    本发明提供了:一种 EVOH 树脂组合物,该组合物经热水处理后可表现出优异的气体阻隔性能,即使置于高温高湿条件下也很少产生水泡;以及一种多层结构,其中包括一层该树脂组合物作为气体阻隔层。具有特定吸水性能的可水合形成的碱土金属盐,特别是完全或部分脱水的碱土金属酸盐,或其混合物。酸选自乳酸、硅酸、磷酸和柠檬酸组成的组。部分脱水的碱土金属盐的含水量不超过 50 wt%。
  • RESIN COMPOSITION AND MULTILAYER STRUCTURE USING SAME
    申请人:The Nippon Synthetic Chemical Industry Co., Ltd.
    公开号:EP3281986A1
    公开(公告)日:2018-02-14
    A resin composition which can suppress the deterioration of performances of a multilayer structure due to moisture absorption regardless that the multilayer structure includes a hygroscopic layer whose performance is deteriorated due to moisture absorption, and a multilayer structure including a layer of the resin composition, are provided. Since the resin composition contains a hydrate-forming alkaline earth metal salt having a specific water absorption property, a multilayer structure comprising a layer of the resin composition can exhibit moisture resistance as a whole of the multilayer structure without affecting the appearance thereof.
    本发明提供了一种无论多层结构是否包含因吸湿而性能变差的吸湿层,都能抑制多层结构因吸湿而性能变差的树脂组合物,以及包含一层该树脂组合物的多层结构。由于该树脂组合物含有具有特定吸水性能的水合碱土金属盐,因此包含一层该树脂组合物的多层结构可作为多层结构的整体表现出防潮性能,而不会影响其外观。
查看更多

同类化合物

(甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (R)-乙基N-甲酰基-N-(1-苯乙基)甘氨酸 (R)-丙酰肉碱-d3氯化物 (R)-4-N-Cbz-哌嗪-2-甲酸甲酯 (R)-3-氨基-2-苄基丙酸盐酸盐 (R)-1-(3-溴-2-甲基-1-氧丙基)-L-脯氨酸 (N-[(苄氧基)羰基]丙氨酰-N〜5〜-(diaminomethylidene)鸟氨酸) (6-氯-2-吲哚基甲基)乙酰氨基丙二酸二乙酯 (4R)-N-亚硝基噻唑烷-4-羧酸 (3R)-1-噻-4-氮杂螺[4.4]壬烷-3-羧酸 (3-硝基-1H-1,2,4-三唑-1-基)乙酸乙酯 (2S,3S,5S)-2-氨基-3-羟基-1,6-二苯己烷-5-N-氨基甲酰基-L-缬氨酸 (2S,3S)-3-((S)-1-((1-(4-氟苯基)-1H-1,2,3-三唑-4-基)-甲基氨基)-1-氧-3-(噻唑-4-基)丙-2-基氨基甲酰基)-环氧乙烷-2-羧酸 (2S)-2,6-二氨基-N-[4-(5-氟-1,3-苯并噻唑-2-基)-2-甲基苯基]己酰胺二盐酸盐 (2S)-2-氨基-3-甲基-N-2-吡啶基丁酰胺 (2S)-2-氨基-3,3-二甲基-N-(苯基甲基)丁酰胺, (2S,4R)-1-((S)-2-氨基-3,3-二甲基丁酰基)-4-羟基-N-(4-(4-甲基噻唑-5-基)苄基)吡咯烷-2-甲酰胺盐酸盐 (2R,3'S)苯那普利叔丁基酯d5 (2R)-2-氨基-3,3-二甲基-N-(苯甲基)丁酰胺 (2-氯丙烯基)草酰氯 (1S,3S,5S)-2-Boc-2-氮杂双环[3.1.0]己烷-3-羧酸 (1R,4R,5S,6R)-4-氨基-2-氧杂双环[3.1.0]己烷-4,6-二羧酸 齐特巴坦 齐德巴坦钠盐 齐墩果-12-烯-28-酸,2,3-二羟基-,苯基甲基酯,(2a,3a)- 齐墩果-12-烯-28-酸,2,3-二羟基-,羧基甲基酯,(2a,3b)-(9CI) 黄酮-8-乙酸二甲氨基乙基酯 黄荧菌素 黄体生成激素释放激素 (1-5) 酰肼 黄体瑞林 麦醇溶蛋白 麦角硫因 麦芽聚糖六乙酸酯 麦根酸 麦撒奎 鹅膏氨酸 鹅膏氨酸 鸦胆子酸A甲酯 鸦胆子酸A 鸟氨酸缩合物